

ONLINE SUPPLEMENTARY CONTENT

Table SI - Baseline characteristics of the 87 patients

Male/female	53 (60.9%)/34 (39.1%)
Age	
At the beginning of follow-up, months	3 (IQR: 1-60)
At first transfusion, years	3 (IQR: 1-6)
Patients <18 years	84 (96.6%)
Transfused elsewhere	39 (44.8%)
Demographic origin	
African	65 (74.7%)
Latin-American	19 (21.8%)
European	2 (2.3%)
Asian	1 (1.2%)
HbS phenotype	
HbSS	83 (95.4%)
HbSβ	3 (3.4%)
HbSC	1 (1.1%)
Therapeutics	
Hydroxyurea	74 (85.1%)
Iron chelation	23 (26.4%)
Splenectomy	10 (11.5%)
SCT	32 (36.8%)
Chronic transfusion therapy	52 (59.8%)
Erythrocytapheresis	13 (14.9%)

HbS: S hemoglobin; SCT: Stem-cell transplantation.

Table SII - RBC serologic antigen frequencies

ABO	
O	41/87 (47.1%)
A	22/87 (25.3%)
B	19/87 (21.8%)
AB	5/87 (5.7%)
Rh	
D	80/87 (92%)
C	31/86 (36%)
c	83/86 (96.5%)
E	16/86 (18.6%)
e	84/86 (97.7%)
Kell	
K	1/86 (1.2%)
Duffy	
Fya	9/69 (13%)
Fyb*	9/27 (33.3%)
Kidd	
Jka	59/66 (89.4%)
Jkb*	12/27 (44.4%)
MNS	
S	25/65 (38.5%)
s*	16/17 (94.1%)

*Be aware that these antigens were only studied in a small proportion of the patients